All In Biotech

Drug Trial Radar · NCT07457229

Radiprodil in Participants With Hepatic Impairment

Phase 1, Open-Label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Radiprodil in Hepatically Impaired Participants

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

May 2027

Study completion Aug 2027

Sponsor

Lead sponsor
GRIN Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1, open-label study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of radiprodil in adults with varying degrees of hepatic impairment compared with healthy participants. Radiprodil is being developed as a potential treatment for GRIN-related neurodevelopmental disorders, tuberous sclerosis complex, and focal cortical dysplasia. Approximately 40 adults aged 18 to 75 years will be enrolled into five cohorts based on liver function (mild, moderate, or severe hepatic impairment) or healthy status. Participants will receive a single 15 mg oral dose of radiprodil and remain in the clinical research unit for intensive PK and safety monitoring through Day 6. The primary objective is to characterize the PK profile of radiprodil in participants with hepatic impairment compared with healthy participants. Safety and tolerability will also be assessed. Results from this study will help determine whether dose adjustments are needed in individuals with impaired liver function.

Conditions

  • Hepatic Impairment

Interventions

  • RadiprodilDrug

    Radiprodil will be administered as a single oral dose of 15 mg (2.0 mL of 7.5 mg/mL oral suspension) on Day 1 under fed conditions. Participants will fast overnight for at least 10 hours prior to dosing and consume a standard breakfast approximately 30 minutes before administration. Study drug will be administered with approximately 240 mL of water. All participants across cohorts will receive the same single-dose regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of RadiprodilTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
  2. Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) of RadiprodilTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
  3. Maximum Observed Plasma Concentration (Cmax) of RadiprodilTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
  4. Time to Maximum Observed Plasma Concentration (Tmax) of RadiprodilTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
  5. Time Before First Quantifiable Plasma Concentration (Tlag) of RadiprodilTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
  6. Apparent Total Body Clearance (CL/F) of RadiprodilTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
  7. Apparent Volume of Distribution Based on the Terminal Phase (Vz/F) of RadiprodilTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
  8. Terminal Elimination Half-Life (t½) of RadiprodilTime frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Epic Medical Research

    DeSoto, Texas · Recruiting

  • Texas Liver Institute

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.